Journal of Neurology

, Volume 254, Issue 4, pp 459–464 | Cite as

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease

A randomized, double blind, placebo-controlled study
  • Camila Andrade Mendes Medeiros
  • Pedro Felipe Carvalhedo de Bruin
  • Lívia Ariane Lopes
  • Maria Cecília Magalhães
  • Maria de Lourdes Seabra
  • Veralice Meireles Sales de Bruin
ORIGINAL COMMUNICATION

Abstract

Insomnia, sleep fragmentation and excessive daytime sleepiness are common in Parkinson's disease (PD) and may contribute to the reduction of cognition and alertness in those patients. Melatonin has been shown to improve sleep in several conditions. In experimental models of PD, melatonin can ameliorate motor symptoms. To evaluate the effect of melatonin on sleep and motor dysfuntion in PD, we studied 18 patients (Hoehn & Yahr I to III) from a PD clinic. Prior to treatment, motor dysfunction was assessed by UPDRS II, III and IV. Subjective sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence by the Epworth Sleepiness Scale (ESS). Full polysomnography (PSG) was performed in all subjects. Patients were then randomized to receive melatonin (3mg) or placebo one hour before bedtime for four weeks. All measures were repeated at the end of treatment. On initial assessment, 14 patients (70%) showed poor quality sleep (PSQI > 6) and eight (40%) excessive daytime sleepiness (ESS > 10). Increased sleep latency (50%), REM sleep without atonia (66%), and reduced sleep efficiency (72%) were found on PSG. Eight patients had an apnea/ hipopnea index greater than 15 but no severe oxygen desaturation was observed. Sleep fragmentation tended to be more severe in patients on lower doses of levodopa (p = 0.07). Although melatonin significantly improved subjective quality of sleep (p = 0.03) as evaluated by the PSQI index, PSG abnormalities were not changed. Motor dysfunction was not improved by the use of melatonin. Undetected differences in motor scores and PSG findings may have been due to a small sample size and a type II error.

Key words

Parkinson's disease melatonin sleep polysomnography sleep apnea 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Larsen JP, Tandberg E (2001) Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 15:267–275PubMedCrossRefGoogle Scholar
  2. 2.
    Clarenbach P (2000) Parkinson's disease and sleep. J. Neurol 247:20–2CrossRefGoogle Scholar
  3. 3.
    Arnulf I (2005) Excessive daytime sleepiness in parkinsonism. Sleep Med 9:185–200CrossRefGoogle Scholar
  4. 4.
    Hebert M, Martin SK, Lee C, Eastman CA (2002) The effects of prior light history on the suppression of melatonin by light in humans. J Pineal Res 33:198–203PubMedCrossRefGoogle Scholar
  5. 5.
    Dijk DJ, Lockley SW (2002) Integration of human sleep-wake regulation and circadian rhythmicity. J Appl Physiol 92:852–862PubMedGoogle Scholar
  6. 6.
    Cagnacci A (1996) Melatonin in elation to physiology in adult humans. J Pineal Res 21:200–213PubMedCrossRefGoogle Scholar
  7. 7.
    Arendt J, Skene DJ (2005) Melatonin as a chronobiotic. Sleep Med Rev 9:25–39PubMedCrossRefGoogle Scholar
  8. 8.
    Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP (2005) Melatonin and sleep in aging population. Exp Gerontol 40:911–925PubMedCrossRefGoogle Scholar
  9. 9.
    Campos FL, Silva-Júnior FP, De Bruin VMS, De Bruin PFC (2004) Melatonin Improves Sleep in Asthma. Am J Resp Crit Care 170:947–951CrossRefGoogle Scholar
  10. 10.
    Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15:164–170PubMedCrossRefGoogle Scholar
  11. 11.
    Absi E, Ayala A, Machado A, Parrado J (2000) Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J Pineal Res 29:40–47PubMedCrossRefGoogle Scholar
  12. 12.
    Willis GL, Armstrong SM (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol Behav 66:785–795PubMedCrossRefGoogle Scholar
  13. 13.
    Rechtshaffen A, Kales A, editors. A Manual Of Standardized Terminology, Techniques And Scoring System For Sleep Stages Of Human Subjects. Los Angeles CA: BIS/BRI, UCLA; 1968Google Scholar
  14. 14.
    Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213PubMedCrossRefGoogle Scholar
  15. 15.
    Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMedGoogle Scholar
  16. 16.
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41–50PubMedCrossRefGoogle Scholar
  17. 17.
    Vgontzas AN, Bixler EO, Kales A, Manfredi RL, Tyson K (1994) Validity and clinical utility of sleep laboratory criteria for insomnia. Int J Neurosci 77:11–21PubMedCrossRefGoogle Scholar
  18. 18.
    Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ (2005) Melatonin for sleep disturbances in Parkinson's Disease. Sleep Med 6:459–466PubMedCrossRefGoogle Scholar
  19. 19.
    Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, Lacomblez L, Golmard JL, Derenne JP, Agid Y (2002) Parkinson's disease and sleepiness: an integral part of PD. Neurology 58:1019–1024PubMedGoogle Scholar
  20. 20.
    Happe S, Anderer P, Pirker W, Klosch G, Gruber G, Saletu B, Zeitlhofer J (2004) Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease. J Neurol 251:1465–1471PubMedCrossRefGoogle Scholar
  21. 21.
    Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O (2005) Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 12:199–207PubMedCrossRefGoogle Scholar
  22. 22.
    Romigi A, Brusa L, Marciani MG, Pierantozzi M, Placidi F, Izzi F, Sperli F, Testa F, Stanzione P (2005) Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic study. J Neurol Sci 228:7–10PubMedCrossRefGoogle Scholar
  23. 23.
    Diederich NJ, Vaillant M, Leischen M, Mancuso G, Golinval S, Nati R, Schlesser M (2005) Sleep apnea syndrome in Parkinson's disease. A casecontrol study in 49 patients. Mov Disord 20:1413–1418PubMedCrossRefGoogle Scholar
  24. 24.
    Monte FS, da Silva-Junior FP, Braga- Neto P, Nobre e Souza MA, Sales de Bruin VM (2004) Snoring and excessive daytime sleepiness in Parkinson's disease. J Neurol Sci 217:41–45CrossRefGoogle Scholar
  25. 25.
    Seabra ML, Bignotto M, Pinto LR Jr, Tufik S (2000) Randomized, doubleblind clinical trial, controlled with placebo, of the toxicology chronic melatonin treatment. J Pineal Res 29:193–200PubMedCrossRefGoogle Scholar
  26. 26.
    Dowling GA, Mastick J, Aminoff MJ (2003) Melatonin treatment for insomnia in Parkinson's disease: A pilot Study. Sleep Research Online 5:99–103Google Scholar
  27. 27.
    Bruguerolle B, Simon N (2002) Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 25:194–201PubMedCrossRefGoogle Scholar
  28. 28.
    Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, Destee A (2003) Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 26:65–72PubMedCrossRefGoogle Scholar
  29. 29.
    Camara Magalhaes S, Vitorino Souza C, Rocha Dias T, Felipe Carvalhedo de Bruin P, Meireles Sales de Bruin V (2005) Lifestyle regularity measured by the social rhythm metric in Parkinson's disease. Chronobiol Int 22:917–924PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • Camila Andrade Mendes Medeiros
    • 2
  • Pedro Felipe Carvalhedo de Bruin
    • 1
  • Lívia Ariane Lopes
    • 1
  • Maria Cecília Magalhães
    • 1
  • Maria de Lourdes Seabra
    • 3
  • Veralice Meireles Sales de Bruin
    • 1
  1. 1.Dept. of MedicineFederal University of CearáFortaleza (Ceará)Brazil
  2. 2.Dept. of PharmacyFederal University of CearáCearáBrazil
  3. 3.Dept. of Psychobiology PauloFederal University of São São PauloBrazil

Personalised recommendations